OBI.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 16:56):

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally...

Stats
Šios dienos apimtis	57 116.00
Vidutinė apimtis	308 797
Rinkos kapitalizacija	11.46M
EPS	£-0.124 ( 2011-06-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.980
ATR14	£0.271 (4.61%)

Ondine Biomedical Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ondine Biomedical Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	£638 000
Bruto pelnas:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2022
Pajamos:	£638 000
Bruto pelnas:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2021
Pajamos:	£2.57M
Bruto pelnas:	£1.25M (48.81 %)
EPS:	£-0.257

FY	2020
Pajamos:	£1.79M
Bruto pelnas:	£649 000 (36.24 %)
EPS:	£-0.0833

Financial Reports:

No articles found.

Ondine Biomedical Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.